Exchange: NASDAQ·Updated 07:30 PM EDT

RLMD News

News
all
press releases
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
Zacks
More News
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks
Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index
Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company"))), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, todayread more...
Benzinga
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call
HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highlighting its bladder cancer potential.read more...
Benzinga
Transcript: Relmada Therapeutics Q1 2026 Earnings Conference Call
read more...
Benzinga
Relmada Therapeutics (NASDAQ:RLMD) Reaches New 1-Year High - Time to Buy?
Relmada Therapeutics (NASDAQ:RLMD) Reaches New 1-Year High - Should You Buy...
MarketBeat
Relmada Therapeutics (RLMD) Projected to Post Quarterly Earnings on Monday
Relmada Therapeutics (NASDAQ:RLMD) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-relmada-therapeutics-inc-stock...
MarketBeat
Relmada Therapeutics (NASDAQ:RLMD) Trading Down 4.3% - Here's What Happened
Relmada Therapeutics (NASDAQ:RLMD) Shares Down 4.3% - What's Next...
MarketBeat

Advertisement|Remove ads.